Novocure Ltd
NVCR12.040USD
-0.500-3.99%
Close 07/25, 16:00（ET）Quotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM
More Details of Novocure Ltd Company
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Company Info
Ticker SymbolNVCR
Company nameNovocure Ltd
IPO dateOct 01, 2015
Founded at2000
CEOMs. Ashley Cordova
Number of employees1488
Security typeOrdinary Share
Fiscal year-endOct 01
AddressNo. 4 The Forum
CitySAINT HELIER
Stock exchangeNASDAQ Global Select Consolidated
CountryJersey
Postal codeJE2 4UF
Phone441534756700
Websitehttps://www.novocure.com/
Ticker SymbolNVCR
IPO dateOct 01, 2015
Founded at2000
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Mr. Martin J. Madden
Mr. Martin J. Madden
Independent Director
Independent Director
18.67K
-5.08%
Ms. Kristin Stafford
Ms. Kristin Stafford
Independent Director
Independent Director
14.27K
+252.06%
Dr. Allyson Ocean, M.D.
Dr. Allyson Ocean, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
93.15M
60.10%
Germany
18.72M
12.08%
France
17.86M
11.52%
Other EMEA countries
11.94M
7.70%
Japan
8.71M
5.62%
Greater China
4.62M
2.98%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor
48.81%
Investment Advisor/Hedge Fund
14.72%
Hedge Fund
12.72%
Individual Investor
10.05%
Research Firm
1.57%
Sovereign Wealth Fund
0.87%
Pension Fund
0.42%
Bank and Trust
0.32%
Venture Capital
0.12%
Other
10.39%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
675
112.27M
100.70%
-3.75M
2025Q1
737
108.90M
97.99%
+1.47M
2024Q4
761
104.07M
94.71%
-2.49M
2024Q3
766
105.53M
97.47%
-2.32M
2024Q2
782
105.08M
97.13%
+3.28M
2024Q1
775
93.94M
87.31%
-7.19M
2023Q4
784
94.40M
88.34%
-2.12M
2023Q3
811
96.26M
90.17%
-961.84K
2023Q2
853
95.14M
89.25%
-1.89M
2023Q1
864
93.47M
88.04%
+2.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
16.49M
14.79%
+257.14K
+1.58%
Mar 31, 2025
The Vanguard Group, Inc.
11.23M
10.07%
-544.61K
-4.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.78M
7.88%
-135.87K
-1.52%
Mar 31, 2025
Wyss (Hansjorg)
8.14M
7.3%
--
--
Apr 04, 2025
Soleus Capital Management, L.P.
5.52M
4.95%
+2.78M
+101.53%
Mar 31, 2025
Capital World Investors
5.22M
4.68%
+400.00K
+8.31%
Mar 31, 2025
State Street Global Advisors (US)
2.59M
2.32%
-52.73K
-2.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.46M
2.21%
+63.41K
+2.64%
Mar 31, 2025
BlackRock Financial Management, Inc.
2.06M
1.85%
+71.86K
+3.61%
Mar 31, 2025
Marshall Wace LLP
1.81M
1.62%
+1.54M
+567.13%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Global X HealthTech ETF
1.92%
SPDR S&P Health Care Equipment ETF
1.85%
ROBO Global Healthcare Technology & Innovation ETF
1.63%
Amplify BlueStar Israel Technology ETF
0.93%
iShares Health Innovation Active ETF
0.53%
VanEck Israel ETF
0.42%
First Trust Small Cap Growth AlphaDEX Fund
0.34%
Global X Aging Population ETF
0.34%
Nuveen ESG Small-Cap ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.23%
View more
Global X HealthTech ETF
Proportion1.92%
SPDR S&P Health Care Equipment ETF
Proportion1.85%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.63%
Amplify BlueStar Israel Technology ETF
Proportion0.93%
iShares Health Innovation Active ETF
Proportion0.53%
VanEck Israel ETF
Proportion0.42%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.34%
Global X Aging Population ETF
Proportion0.34%
Nuveen ESG Small-Cap ETF
Proportion0.25%
ProShares Ultra Nasdaq Biotechnology
Proportion0.23%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
